The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Transcription factors for genetically modified cells is a key innovation area in the pharmaceutical industry

Transcription factors are proteins which control gene expression by controlling the rate of transcription of genetic information from DNA to RNA. Artificial transcription factors such as CRISPR-CAS9 are widely used to precisely regulate gene expression in various genetically modified cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 40+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of transcription factors for genetically modified cells.

Key players in the transcription factors for genetically modified cells space – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to transcription factors for genetically modified cells

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Fujifilm Holdings 162 Unlock Company Profile
I'rom Group 51 Unlock Company Profile
Allele Biotechnology and Pharmaceuticals 48 Unlock Company Profile
Ministry of Trade and Industry, Singapore 43 Unlock Company Profile
BioNTech 41 Unlock Company Profile
Johnson & Johnson 36 Unlock Company Profile
Genesis Technologies 34 Unlock Company Profile
Cellscript 33 Unlock Company Profile
BioLamina 33 Unlock Company Profile
Taiga Biotechnologies 29 Unlock Company Profile
Lonza Group 22 Unlock Company Profile
National Cancer Center 22 Unlock Company Profile
Children's Medical Center 20 Unlock Company Profile
F. Hoffmann-La Roche 20 Unlock Company Profile
Mesoblast 16 Unlock Company Profile
ReNeuron Group 15 Unlock Company Profile
Daiichi Sankyo 15 Unlock Company Profile
Mayo Clinic 14 Unlock Company Profile
New World Laboratories 13 Unlock Company Profile
TRON gGmbH 13 Unlock Company Profile
Kangstem Biotech 12 Unlock Company Profile
Bristol-Myers Squibb 12 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 11 Unlock Company Profile
Stemlab 10 Unlock Company Profile
Touchlight Genetics 10 Unlock Company Profile
Mclean Hospital 10 Unlock Company Profile
Hong Guan 10 Unlock Company Profile
Scripps Health 10 Unlock Company Profile
Takara Holdings 10 Unlock Company Profile
City of Hope 8 Unlock Company Profile
Wellcome Trust 8 Unlock Company Profile
Green Cross Holdings 7 Unlock Company Profile
Max-Planck-Gesellschaft 7 Unlock Company Profile
Centre National de la Recherche Scientifique 7 Unlock Company Profile
LifeSci Index Partners 7 Unlock Company Profile
Orig3N 7 Unlock Company Profile
UAB Research Foundation 7 Unlock Company Profile
General Hospital 7 Unlock Company Profile
Cedars-Sinai Health System 6 Unlock Company Profile
Riken 6 Unlock Company Profile
ReproCELL 6 Unlock Company Profile
Novagenesis 5 Unlock Company Profile
Guangzhou Biocare Biotechnology 5 Unlock Company Profile

Source: GlobalData Patent Analytics

I'rom Group is the leading patent holder for transcription factors for genetically modified cells. The company has filed several patents for the production of induced pluripotent stem cells by using transcription factors. The Company is also developing several other innovations using transcription factors to produce genetically modified cells.

In terms of application diversity, Kangstem Biotech is the top company, followed by Cellscript and Novagenesis. By means of geographic reach, New World Laboratories holds the top position. Stemlab, and Research and Touchlight Genetics stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.